Exosomes in Multiple Myeloma: from bench to bedside
Multiple myeloma (MM) remains till today an incurable plasma cell malignancy which develops in the bone marrow (BM). This BM is partially responsible for protec
Conclusion/Relevance: In this review we will summarize the current findings of exosome-related processes in the BM and describe not only the current treatment strategies to counter them but also how exosomes can be harnessed to deliver toxic payloads. Finally, an overview of the different clinical studies which investigate EV cargo as potential...
Role of cytokines in multiple myeloma: IL-1RN and IL-4 VNTR polymorphisms
Source : https://www.sciencedirect.com/science/article/abs/pii/S1043466622000606?via=ihub
The IL-1 receptor antagonist (IL-1Ra or IL-1RN) functions as a competitive antagonist of the cell surface IL-1 receptor. * IL-4 is a potent anti-inflammatory cytokine. * It was aimed to...
Conclusions: In conclusion, with this study, the effects of IL-1RN VNTR and IL-4 VNTR polymorphisms on MM were evaluated for the first time in the literature. This study will shed light on ones on cytokine-MM relationship and epigenetic mechanisms.
Current Approaches to Management of Newly Diagnosed Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35234302/
Major developments in the treatment of multiple myeloma over the past decade have led to a continued improvement in survival. Significant progress has been made with deeper and longer remissions...
Conclusion/Relevance: Among transplant ineligible patients, those with standard risk MM should receive DRd continued until disease progression, while bortezomib containing regimens (VRd or VRd lite) can be considered for high-risk patients. Finally, standard risk patients should receive lenalidomide maintenance after induction/ASCT, while a...
A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment - Cell Death & Disease
Source : https://www.nature.com/articles/s41419-022-04651-w
Despite several approved therapeutic modalities, multiple myeloma (MM) remains an incurable blood malignancy and only a small fraction of patients achieves prolonged disease control. The common anti-MM treatment targets proteasome...
Conclusion: Overall our findings suggest that disulfiram repurposing particularly if combined with copper supplementation may offer a promising and readily available treatment option for patients suffering from relapsed and/or therapy-resistant multiple myeloma.
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35201323/
Anti-CD38 monoclonal antibodies (mAbs) represent a breakthrough in the treatment of multiple myeloma (MM), yet some patients fail to respond or progress quickly with this therapy, highlighting the need for...
Relevance: These results highlight the preclinical efficacy of SAR442085 and support the current evaluation of this next-generation anti-CD38 antibody in phase I clinical development in patients with relapsed/refractory MM.